Satellite Banner
Technology Networks Header
Friday, July 25, 2014
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
Schizophrenia’s Genetic Skyline Rising
Suspect common variants soar from 30 to 108 - NIH-funded study.
UK Government Must Do More to Reduce Risk of vCJD Infection
Report recommends that UK Government commission a full assessment of the risks currently faced by the UK blood supply.
Future Directions of Forensic DNA Databases
With the great success of the use of forensic DNA databases, new challenges are emerging.
Current Developments in Forensic Interpretation of Mixed DNA Samples
It is of great significance to develop innovative experimental techniques and software appropriate for complex mixed DNA analysis.
Preparation of Phosphines Through C–P Bond Formation
This article reviews some of the most important C–P bond formation strategies, organizing them according to the hybridization of carbon in the newly formed C–P bond.
Simultaneous Determination of Six Flame Retardants in Water
The work aimed to develop an analytical procedure for the extraction and simultaneous determination of selected flame retardants.
NIST Instrument Enables High-speed Chemical Imaging of Tissues
Researchers have demonstrated a dramatically improved technique for analyzing biological cells and tissues based on characteristic molecular vibration "signatures."
Transplanting Gene into Injured Hearts Creates Biological Pacemakers
Researchers develop first minimally invasive gene therapy procedure to treat heart rhythm disorders by transforming ordinary heart muscle cells into specialized rhythm-keeping cells, potentially eliminating future need for electronic pacemakers.
Common Gene Variants Account for Most Genetic Risk for Autism
Roles of heritability, mutations, environment estimated - NIH-funded study.
Using LC-MS to Analyse Sulfonamides in Food Grade Honey
Sulfonamides are one of a number of groups of chemicals whose presence in honey is limited by international regulations.
Scroll Up
Scroll Down
Return
An ACE Method for Monitoring Protein-protein Interactions (PPIs)
Carol Austin, Selcia, speaking at Discovery Chemistry Congress 2013.
Date Posted: Tuesday, April 30, 2013
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Selcia and Cantab Announce Drug Discovery Collaboration
Partnership to accelerate Cantab’s programme to develop improved antibiotics for multidrug resistant Gram-negative bacterial infections.
Thursday, September 05, 2013
Selcia Introduces New Prolyl Isomerase Screening Service
Selcia Limited has announced the launch of a new platform to enable drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (“PPIases”).
Friday, February 01, 2013
Selcia and NeuroVive to Develop New Mitochondrial Medicines
Selcia Limited and NeuroVive Pharmaceutical AB have signed a research collaboration agreement to develop new medicines and drug compounds targeting mitochondrial physiology and pathophysiology.
Monday, October 10, 2011
Selcia and ExonHit Therapeutics Announce Successful Fragment Screening Collaboration
Successful completion of a drug discovery project with ExonHit Therapeutics using Selcia’s fragment screening technology.
Thursday, April 21, 2011
Selcia Appoints Simon Saxby as CEO and Andreas Rummelt to its Board
Simon Saxby brings successful leadership and executive management experience to the role of Selcia’s CEO and Andreas is recognized as a global expert in drug development and will further enhance the strategic strength of Selcia’s Board.
Thursday, February 24, 2011
Selcia and Gilead Sciences Extend Liver Disease Drug Discovery Collaboration
Selcia Limited announced a drug discovery collaboration agreement with Gilead Sciences Inc. Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead’s liver disease research programmes.
Tuesday, November 30, 2010
Convergence Pharmaceuticals and Selcia Announce Drug Discovery Collaboration Around Chronic Pain
Convergence Pharmaceuticals Limited, the new company focused on the development of novel and high value analgesic medicines, and Selcia Limited, a contract research organisation, today are pleased to announce that they have entered into a drug discovery collaboration to identify and develop high quality candidate molecules for the treatment of chronic pain.
Thursday, November 25, 2010
Simon Saxby Joins Board at Selcia
Selcia Limited, a leading provider of contract research services in 14-C custom radiolabelling, integrated drug discovery, fragment screening and medicinal chemistry today announced the high profile appointment of Simon Saxby to the Board as a non-executive director.
Monday, June 28, 2010
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv